4.4 Review

Nanocarrier-mediated curcumin delivery: An adjuvant strategy for CNS disease treatment

Journal

EXPERIMENTAL BIOLOGY AND MEDICINE
Volume -, Issue -, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/15353702231211863

Keywords

Nanocarriers; curcumin; CNS diseases; neurodegenerative disorders; intranasal delivery; blood-brain barrier

Ask authors/readers for more resources

Neurological disorders pose a global challenge and require innovative therapeutic approaches. Curcumin, a natural compound with antioxidant and anti-inflammatory properties, shows potential as an adjuvant therapy for central nervous system diseases. However, its limited bioavailability and permeability to the blood-brain barrier hinder its therapeutic efficacy. Nanocarriers can facilitate curcumin delivery, improving its bioavailability and blood-brain barrier permeability, and revolutionizing treatment outcomes for neurological disorders.
Neurological disorders are a major global challenge, which counts for a substantial slice of disease burden around the globe. In these, the challenging landscape of central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and neuro-AIDS, demands innovative and novel therapeutic approaches. Curcumin, a versatile natural compound with antioxidant and anti-inflammatory properties, shows great potential as a CNS adjuvant therapy. However, its limited bioavailability and suboptimal permeability to the blood-brain barrier (BBB) hamper the therapeutic efficacy of curcumin. This review explores how nanocarrier facilitates curcumin delivery, which has shown therapeutic efficacy for various non-CNS diseases, for example, cancers, and can also revolutionize the treatment outcomes in patients with CNS diseases. Toward this, intranasal administration of curcumin as a non-invasive CNS drug delivery route can also aid its therapeutic outcomes as an adjuvant therapy for CNS diseases. Intranasal delivery of nanocarriers with curcumin improves the bioavailability of curcumin and its BBB permeability, which is instrumental in promoting its therapeutic potential. Furthermore, curcumin's inhibitory effect on efflux transporters will help to enhance the BBB and cellular permeability of various CNS drugs. The therapeutic potential of curcumin as an adjuvant has the potential to yield synergistic effects with CNS drugs and will help to reduce CNS drug doses and improve their safety profile. Taken together, this approach holds a promise for reshaping CNS disease management by maximizing curcumin's and other drugs' therapeutic benefits.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available